PDF(Pubmed)
Abstract：
Preeclampsia (PE) is a leading cause of maternal and neonatal morbidity and mortality worldwide. Several studies demonstrated the role of lncRNAs and miRNAs in the pathogenesis of preeclampsia; the aim was to detect the expression profiles of serum LncRNA ANRIL, miR-186, miR-181a, and MTMR-3 in patients with preeclampsia. The study included 160 subjects divided into 80 subjects considered as a control group, 80 patients with preeclampsia. We found that there was a significant difference between the preeclampsia and control groups with up-regulation of miR-186 median (IQR) = 4, 29 (1.35-7.73) (P < 0.0001), miR-181a median (IQR) = 2.45 (0.83-6.52) (P = 0.028), and downregulation of lncRNA ANRIL median (IQR) = 0.35(0.28-0.528) (P < 0.0001), MTMR median (IQR) = 0.32(0.155-1.11), (P < 0.0001). ROC curve of lncRNA ANRIL, miR-186, miR-181a, and MTMR-3 in preeclampsia patients showing the roles of these markers in the diagnosis of preeclampsia. In conclusion, serum LncRNA ANRIL, miR-186, miR-181a, and MTMR-3 could be promising biomarkers in the diagnosis of preeclampsia.
摘要：
先兆子痫（PE）是全球孕产妇和新生儿发病和死亡的主要原因。多项研究表明lncRNAs和miRNAs在子痫前期发病机制中的作用;目的是检测血清LncRNAANRIL的表达谱,miR-186,miR-181a,和MTMR-3在子痫前期患者中的应用。该研究包括160名受试者，分为80名受试者作为对照组，子痫前期患者80例。我们发现先兆子痫组和对照组之间存在显着差异，miR-186的上调中位数（IQR）=4,29（1.35-7.73）（P<0.0001），miR-181a中位数（IQR）=2.45（0.83-6.52）（P=0.028），lncRNAANRIL的下调中位数（IQR）=0.35（0.28-0.528）（P<0.0001），MTMR中位数（IQR）=0.32（0.155-1.11），(P<0.0001)。lncRNAANRIL的ROC曲线，miR-186,miR-181a,和MTMR-3在子痫前期患者中显示了这些标志物在子痫前期诊断中的作用。总之,血清LncRNAANRIL，miR-186,miR-181a,和MTMR-3可能是诊断先兆子痫的有希望的生物标志物。
